Genetic variations of morphine transporters: prevalence of polymorphisms of the ABCB1 gene among oncology patients of palliative profile

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective: Assessment of the prevalence of clinically significant single nucleotide polymorphisms of the ABCB1 gene (rs1128503, rs2032582, rs1045642) in palliative cancer patients receiving morphine in order to substantiate the prospects of a pharmacogenetic approach to personalized analgesic therapy.

Materials and methods: The study included 86 patients with cancer in the palliative stage and receiving morphine, as well as 100 control patients without cancer. Genotyping of ABCB1 polymorphisms was performed using real-time polymerase chain reaction. The dynamics of pain syndrome was also assessed using a visual analog scale (VAS) at three stages of therapy.

Results: A high frequency of heterozygous CT variants for rs1128503 and rs1045642 polymorphisms was established. VAS analysis showed a decrease in pain syndrome from 8 to 2 points after the start of morphine therapy, which confirms its effectiveness.

Conclusion: ABCB1 gene polymorphisms may play a significant role in the variability of response to morphine in cancer patients. The obtained data emphasize the need for further research to develop personalized pain relief strategies taking into account genetic characteristics.

Texto integral

Acesso é fechado

Sobre autores

Evgeny Khaitovich

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Autor responsável pela correspondência
Email: eukhad@gmail.com
ORCID ID: 0000-0003-2629-9250

Postgraduate Student, Department of Clinical Pharmacology and Propaedeutics of Internal Medicine, Clinical Pharmacologist

Rússia, Moscow

Evgenia Shikh

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: chih@mail.ru
ORCID ID: 0000-0001-6589-7654

Dr. Sci. (Med.), Professor, Corr. Member of the RAS, Head of the Department of Clinical Pharmacology and Propaedeutics of Internal Medicine

Rússia, Moscow

Arif Ibragimov

Moscow Multidisciplinary Center for Palliative Care, Moscow Healthcare Department

Email: eukhad@gmail.com

Chief Physician

Rússia, Moscow

Mark Gergel

Moscow Multidisciplinary Center for Palliative Care, Moscow Healthcare Department

Email: eukhad@gmail.com

Palliative Care Physician

Rússia, Moscow

Anton Borisov

Moscow Multidisciplinary Center for Palliative Care, Moscow Healthcare Department

Email: eukhad@gmail.com

Palliative Care Physician

Rússia, Moscow

Ruslan Kazakov

Scientific Center for Expertise of Medical Products

Email: eukhad@gmail.com
ORCID ID: 0000-0003-0802-4229

Cand. Sci. (Biol.), Leading Researcher

Rússia, Moscow

Bibliografia

  1. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59–98. https://dx.doi.org/10.2165/00003088-200342010-00003
  2. Tanabe M., Ieiri I., Nagata N., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297(3):1137–43.
  3. Schaeffeler E., Eichelbaum M., Brinkmann U., et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358(9279):383–4. https://dx.doi.org/10.1016/S0140-6736(01)05579-9
  4. Zhou Z., Chen Q., Zuo D., et al. ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis. Int J Clin Exp Med. 2015;8(1):265–72.
  5. Rychlik-Sych M., Barańska M., Dudarewicz M., et al. Haplotypes of ABCB1 1236C >T (rs1128503), 2677G >T/A (rs2032582), and 3435C >T (rs1045642) in patients with bullous pemphigoid. Arch Dermatol Res. 2018;310(6):515–22. https://dx.doi.org/10.1007/s00403-018-1842-8
  6. Клинические рекомендации. Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи. 2023-2024-2025 (15.02.2023). [Clinical guidelines. Chronic pain syndrome (CPS) in adult patients requiring palliative care. 2023-2024-2025 (15.02.2023). (In Russ.)].
  7. Хайтович Е.Д., Ших Е.В., Ибрагимов А.Н. и др. Полиморфизм рецепторных и ферментативных генов, ассоциированных с выраженностью анальгетического эффекта морфина у онкологических пациентов паллиативного профиля. Фармакология & Фармакотерапия. 2025;1:42–8. [Khaitovich E.D., Shikh E.V., Ibragimov A.N. et al. Polymorphism of receptor and enzymatic genes associated with the severity of the analgesic effect of morphine in palliative cancer patients. Pharmacology & Pharmacotherapy. 2025;1:42–8. (In Russ.)]. https://dx.doi.org/10.46393/27132129_2025_1_42–48
  8. Когония Л.М., Волошин В.Г., Когония Л.М. и др. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. Злокачественные опухоли. 2016;4(Спецвыпуск 2)):474–85. [Kogoniya L.M., Voloshin V.G., Kogoniya L.M. et al. Practical guidelines for the treatment of chronic pain syndrome in cancer patients. Malignant tumors. 2016;4(Special issue 2)):474–85. (In Russ.)].
  9. Ziegler L., Mulvey M., Blenkinsopp A., et al. Opioid prescribing for patients with cancer in the last year of life: A longitudinal population cohort study. Pain. 2016;157(11):2445–51. https://dx.doi.org/10.1097/j.pain.0000000000000656
  10. Ross J.R., Riley J., Taegetmeyer A.B., et al. Genetic variation and response to morphine in cancer patients: Catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112(6):1390–403. https://dx.doi.org/10.1002/cncr.23292

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2025